CINA_STRGV
ID CINA_STRGV Reviewed; 78 AA.
AC P29827;
DT 01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT 01-APR-1993, sequence version 1.
DT 25-MAY-2022, entry version 68.
DE RecName: Full=Lantibiotic cinnamycin;
DE AltName: Full=Lanthiopeptin;
DE AltName: Full=Lantibiotic Ro 09-0198;
DE Flags: Precursor;
GN Name=cinA; Synonyms=rocA;
OS Streptomyces griseoverticillatus (Streptoverticillium griseoverticillatum).
OC Bacteria; Actinobacteria; Streptomycetales; Streptomycetaceae;
OC Streptomyces; Streptomyces cinnamoneus group.
OX NCBI_TaxID=68215;
RN [1]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC STRAIN=MAR 164C-MY6;
RX PubMed=2070795; DOI=10.1111/j.1432-1033.1991.tb16138.x;
RA Kaletta C., Entian K.-D., Jung G.;
RT "Prepeptide sequence of cinnamycin (Ro 09-0198): the first structural gene
RT of a duramycin-type lantibiotic.";
RL Eur. J. Biochem. 199:411-415(1991).
RN [2]
RP PROTEIN SEQUENCE OF 60-78.
RX PubMed=2125590; DOI=10.7164/antibiotics.43.1403;
RA Fredenhagen A., Fendrich G., Marki F., Marki W., Gruner J., Raschdorf F.,
RA Peter H.H.;
RT "Duramycins B and C, two new lanthionine containing antibiotics as
RT inhibitors of phospholipase A2. Structural revision of duramycin and
RT cinnamycin.";
RL J. Antibiot. 43:1403-1412(1990).
RN [3]
RP PROTEIN SEQUENCE OF 60-78, AND HYDROXYLATION AT ASP-74.
RX PubMed=2544544; DOI=10.7164/antibiotics.42.837;
RA Naruse N., Tenmyo O., Tomita K., Konishi M., Miyaki T., Kawaguchi H.,
RA Fukase K., Wakamiya T., Shiba T.;
RT "Lanthiopeptin, a new peptide antibiotic. Production, isolation and
RT properties of lanthiopeptin.";
RL J. Antibiot. 42:837-845(1989).
CC -!- FUNCTION: Can act as inhibitor of the enzyme phospholipase A2, and of
CC the angiotensin-converting enzyme. Shows inhibitory activities against
CC herpes simplex virus and immunopotentiating activities. Its
CC antimicrobial activities are not very pronounced.
CC -!- PTM: Maturation of lantibiotics involves the enzymatic conversion of
CC Thr, and Ser into dehydrated AA and the formation of thioether bonds
CC with cysteine or the formation of dialkylamine bonds with lysine. This
CC is followed by membrane translocation and cleavage of the modified
CC precursor.
CC -!- SIMILARITY: Belongs to the type B lantibiotic family. {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; X58545; CAA41436.1; -; Genomic_DNA.
DR PIR; A45767; EWSMCN.
DR PIR; S17181; EWSMYG.
DR PDB; 2DDE; NMR; -; A=60-78.
DR PDBsum; 2DDE; -.
DR AlphaFoldDB; P29827; -.
DR SMR; P29827; -.
DR DrugBank; DB04731; 1-ACETYL-2-LYSO-SN-GLYCERO-3-PHOSPHOETHANOLAMINE.
DR GO; GO:0005102; F:signaling receptor binding; IEA:UniProtKB-KW.
DR GO; GO:0019835; P:cytolysis; IEA:UniProtKB-KW.
DR GO; GO:0042742; P:defense response to bacterium; IEA:UniProtKB-KW.
DR InterPro; IPR046016; DUF5973.
DR Pfam; PF19398; DUF5973; 1.
PE 1: Evidence at protein level;
KW 3D-structure; Antibiotic; Antimicrobial; Bacteriocin;
KW Direct protein sequencing; Hydroxylation; Lantibiotic; Thioether bond.
FT PROPEP 1..59
FT /evidence="ECO:0000255"
FT /id="PRO_0000017148"
FT PEPTIDE 60..78
FT /note="Lantibiotic cinnamycin"
FT /id="PRO_0000017149"
FT MOD_RES 74
FT /note="(3R)-3-hydroxyaspartate"
FT /evidence="ECO:0000269|PubMed:2544544"
FT CROSSLNK 60..77
FT /note="Beta-methyllanthionine (Cys-Thr)"
FT CROSSLNK 63..73
FT /note="Lanthionine (Ser-Cys)"
FT CROSSLNK 64..70
FT /note="Beta-methyllanthionine (Cys-Thr)"
FT CROSSLNK 65..78
FT /note="Lysinoalanine (Ser-Lys)"
FT STRAND 65..72
FT /evidence="ECO:0007829|PDB:2DDE"
SQ SEQUENCE 78 AA; 8205 MW; 0ACDAE6BA54E5E7A CRC64;
MTASILQQSV VDADFRAALL ENPAAFGASA AALPTPVEAQ DQASLDFWTK DIAATEAFAC
RQSCSFGPFT FVCDGNTK